-$0.62 Earnings Per Share Expected for Solid Biosciences Inc (NASDAQ:SLDB) This Quarter

Wall Street brokerages expect Solid Biosciences Inc (NASDAQ:SLDB) to announce earnings per share of ($0.62) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Solid Biosciences’ earnings, with the highest EPS estimate coming in at ($0.58) and the lowest estimate coming in at ($0.66). Solid Biosciences posted earnings per share of ($0.55) in the same quarter last year, which indicates a negative year-over-year growth rate of 12.7%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Solid Biosciences will report full-year earnings of ($2.85) per share for the current fiscal year, with EPS estimates ranging from ($3.05) to ($2.68). For the next financial year, analysts expect that the business will post earnings of ($2.06) per share, with EPS estimates ranging from ($2.17) to ($1.91). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Solid Biosciences.

Solid Biosciences (NASDAQ:SLDB) last posted its earnings results on Wednesday, August 14th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05.

A number of research analysts have recently issued reports on SLDB shares. Chardan Capital upgraded shares of Solid Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $7.50 to $10.00 in a research report on Friday, August 16th. Citigroup set a $6.00 price target on shares of Solid Biosciences and gave the stock a “hold” rating in a research report on Thursday, May 16th. Goldman Sachs Group downgraded shares of Solid Biosciences from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $5.00 to $4.00 in a research report on Tuesday, May 14th. Zacks Investment Research upgraded shares of Solid Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 17th. Finally, ValuEngine upgraded shares of Solid Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $8.21.

In related news, Director Life Sciences Maste Perceptive acquired 2,822,581 shares of the stock in a transaction dated Thursday, July 25th. The stock was bought at an average price of $4.65 per share, for a total transaction of $13,125,001.65. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 31.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in SLDB. Geode Capital Management LLC increased its stake in Solid Biosciences by 25.4% during the 4th quarter. Geode Capital Management LLC now owns 168,090 shares of the company’s stock valued at $4,504,000 after purchasing an additional 34,060 shares in the last quarter. Emory University lifted its stake in Solid Biosciences by 335.0% in the 1st quarter. Emory University now owns 298,887 shares of the company’s stock valued at $2,750,000 after buying an additional 230,173 shares in the last quarter. Virtu Financial LLC purchased a new stake in Solid Biosciences in the 1st quarter valued at approximately $186,000. Bank of New York Mellon Corp lifted its stake in Solid Biosciences by 35.7% in the 4th quarter. Bank of New York Mellon Corp now owns 56,703 shares of the company’s stock valued at $1,520,000 after buying an additional 14,925 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Solid Biosciences in the 1st quarter valued at approximately $325,000. Institutional investors own 60.06% of the company’s stock.

NASDAQ:SLDB traded down $0.05 during mid-day trading on Thursday, hitting $9.03. 456,928 shares of the company’s stock were exchanged, compared to its average volume of 719,732. The firm has a market capitalization of $329.27 million, a P/E ratio of -4.01 and a beta of 2.07. Solid Biosciences has a fifty-two week low of $4.32 and a fifty-two week high of $54.54. The company has a current ratio of 5.73, a quick ratio of 5.73 and a debt-to-equity ratio of 0.08. The company has a 50 day simple moving average of $5.87 and a 200-day simple moving average of $7.88.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Read More: Initial Public Offering (IPO)

Get a free copy of the Zacks research report on Solid Biosciences (SLDB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.